AstraZeneca collaborates with Celgene Corporation to develop PD-L1 inhibitor programme
AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers.
AstraZeneca & Innate Pharma announce global co-development & commercialisation collaboration
AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology.
AstraZeneca and Bina collaborate to deploy genomic management solution in R&D
AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme and to further develop the Bina Genomic Management Solution (GMS).
AstraZeneca announces latest data for investigational non-small cell lung cancer medicine
Late breaking data presented at the European Lung Cancer Congress 2015 shows delay in disease progression of over a year for AstraZeneca's investigational non-small cell lung cancer medicine AZD9291.
Selumetinib granted Orphan Drug Designation by US FDA for treatment of uveal melanoma
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.
FDA Advisory Committee reviews SAVOR outcomes study results
FDA Advisory Committee reviews SAVOR outcomes study results for ONGLYZA® (saxagliptin) and KOMBIGLYZE® XR (saxagliptin and metformin HCI extended-release).
Tremelimumab granted Orphan Drug Designation by US FDA for malignant mesothelioma treatment
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the anti-CTLA-4 monoclonal antibody, tremelimumab, for the treatment of malignant mesothelioma.
AstraZeneca and PatientsLikeMe announce global research collaboration
A five-year agreement is focused on improving health outcomes for patients across AstraZeneca’s main therapy areas.
AstraZeneca showcases oncology science at American Association for Cancer Research AGM 2015
AstraZeneca will present new data at the American Association for Cancer Research (AACR) annual meeting in Philadelphia this weekend, demonstrating the strength and depth of its early stage oncology pipeline.
AstraZeneca joins Genomics England consortium
AstraZeneca today announced that it has joined a public-private consortium with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project.
AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
AstraZeneca & Daiichi Sankyo to jointly commercialise MOVANTIK in the US
AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for MOVANTIK™ (naloxegol) in the US, in line with the Company’s strategy of delivering value through its own development and commercial capabilities as well as through external collaboration.
AstraZeneca's Scientific Review Board to support clinical trial data transparency commitment
AstraZeneca today announced the creation of a Scientific Review Board that will act independently to assess requests from external researchers which include patient level data.
AstraZeneca's positive Phase III top-line results for PT003 from PINNACLE 1/2 studies in COPD
AstraZeneca today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).
PEGASUS-TIMI 54 study results
PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack. Data from 21,000 patient study presented at American College of Cardiology 64th Annual Scientific Session and simultaneously published in New England Journal of Medicine
AstraZeneca to collaborate with key Singapore research organisations in heart failure
AstraZeneca today announced a two year collaboration with leading organisations in Singapore, including the Agency for Science, Technology and Research (A*STAR), National University Heart Centre, Singapore (NUHCS) and National University of Singapore, to support research into new therapies for heart failure.
AstraZeneca to participate in US FDA Endocrinologic and Metabolic Drugs Advisory Committee
AstraZeneca has announced it will participate in the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on 14 April 2015 to discuss the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial for ONGLYZA® (saxagliptin) and Kombiglyze® XR (saxagliptin and metformin HCI extended-release).
AstraZeneca completes rights acquisition to Actavis’ branded portfolio in US & Canada
AstraZeneca today announced that it has completed the transaction to acquire the rights to Actavis’ branded respiratory business in the US and Canada.
AstraZeneca to create stand-alone company for small molecule early-stage antibiotic R&D
In line with AstraZeneca’s strategy to sharpen its focus on three main therapy areas, the company is changing the structure of its small molecule early-stage anti-infectives research and development.
AstraZeneca and Orca Pharmaceuticals announce research collaboration
AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class RORγ inhibitors to treat auto-immune diseases.
US District Court: PULMICORT RESPULES® (budesonide inhalation suspension) patent litigation
AstraZeneca today announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 (“the ‘834 patent”), protecting PULMICORT RESPULES in the US, is invalid.
AstraZeneca PLC fourth quarter and full year results 2014
AstraZeneca's financial results for 2014 are in line with the upgraded Company guidance given with its third quarter 2014 results.
AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
A new agreement strengthens AstraZeneca’s aclidinium respiratory franchise and adds immediate revenues with long-term growth potential.
AstraZeneca receives planning consent for new global R&D centre and corporate HQ in Cambridge
AstraZeneca today announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City. The purpose built facility will be located on the Cambridge Biomedical Campus and will be home to approximately 2,000 employees.
AstraZeneca collaborates to use CRISPR for genome editing across its drug discovery platform
AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas.